))
015 - Novel technology enables encapsulated cell therapies without triggering fibrosis
Archived series ("HTTP Redirect" status)
Replaced by: Cell Culture Dish Podcast
When?
This feed was archived on January 04, 2018 07:42 (
Why? HTTP Redirect status. The feed permanently redirected to another series.
What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 194415075 series 1874157
Content provided by The Cell Culture Dish. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by The Cell Culture Dish or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this podcast, we interviewed Dr. Paul Wotton, CEO, about Sigilon Therapeutics’ discovery platform. The platform combines cell engineering and biocompatible Afibromer™ technology to enable cell therapies that do not trigger fibrosis
22 episodes
Share
